

Eleven Biotherapeutics

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 08-Feb-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

Eleven Biotherapeutics

COMPANY OVERVIEW

| | |
|--|---|
| Company Name | Eleven Biotherapeutics |
| Parent Company Name | Eleven Biotherapeutics |
| Website | http://www.elevenbio.com/ |
| Country | US |
| Number of Drugs in Active Development | 4 |
| Number of Inactive Drugs | 5 |
| Number of Patents as Owner | 12 |
| Number of Patents as Third Party | 2 |
| Number of Deals | 2 |
| Key Indications | Xerophthalmia, Diabetic macular edema, Inflammatory disease, Allergy, Diabetic eye disease, Autoimmune disease, Ocular disease, Allergic conjunctivitis, Cancer, Rheumatoid arthritis |
| Key Target-based Actions | IL-1 antagonist, IL-17 antagonist, Type I IL-1 receptor antagonist, IL-6 antagonist, Interleukin-6 ligand inhibitor, Factor VIII agonist, GDF-8 antagonist, Interleukin-1 ligand modulator, Albumin agonist, IL-23 antagonist, Interleukin-1 beta ligand inhibitor, Interleukin-1 beta ligand modulator, Type I IL-1 receptor modulator |
| Key Technologies | Biological therapeutic, Peptide, Parenteral formulation unspecified, Ophthalmic formulation, Antibody, Injectable formulation, Protein chimeric, Dermatological formulation, Local formulation unspecified, Transdermal formulation |

COMPANY PROFILE

SUMMARY

Eleven Biotherapeutics aims to develop protein-based therapeutics, with an initial focus on inflammatory conditions and coagulation disorders.

FINANCIAL

In November 2014, the company entered into an agreement for the sale of 1,743,680 shares of its common stock at \$11.47 per share and warrants to purchase approximately 871,840 shares of common stock at a price of \$15 per share. The gross proceeds were expected to be \$20 million. At that time, the transaction was expected to be closed on December 1, 2014 and the warrants would expire in three years from the date of issuance.

March 2014, the company was added to the Russell 2000 and Russell 3000 Indexes.

In January 2014, the company filed a registration statement on Form S-1 for a proposed initial public offering of shares of its common stock. In February 2014, the company priced the offering of 5 million common stock shares at a price of \$10 each. The underwriters were granted a 30-day option to buy up to 750,000 additional shares of common stock to cover over-allotments, at the public offering price less the underwriting discount. Eleven's common stock began trading on the NASDAQ Global Market under the ticker symbol 'EBIO'. Later that month, the company closed the IPO and issued 5,750,000 common stock shares including 750,000 shares of common stock upon full exercise by the underwriters. By May 2014, the company raised net proceeds of approximately \$50.2 million from the initial public offering.

In May 2012, the company secured \$20 million in a series A equity financing, expanding the total amount raised to \$45 million.

In February 2010, Eleven raised \$35 million in a series A financing.

[Return to Table of Contents](#)



COMPANY FINANCIALS

SHARE INFORMATION

| | |
|--------------------------------------|-------------------|
| Close Price (USD) | 10.76 |
| Change (USD) | -0.40 (-3.58%) |
| Previous Close Price (USD) | 11.16 |
| Volume | 23,927 |
| 52-Week High (USD) | 19.33 |
| 52-Week Low (USD) | 9.50 |
| Date | 06-Feb-2015 |
| Exchange | NASDAQ(COMPOSITE) |
| Current Number of Shares Outstanding | 16,289,359 |
| Current Market Capitalization | 175,273,503 |
| EPS (Date Reported) | -2.42377 |

STOCK PERFORMANCE




MAJOR SHAREHOLDERS

[Return to Table of Contents](#)

| Shareholder | Type | Country | Shares held | % of shares held | Change in holding | % changes in shares held | Date |
|---------------------------------|-----------------------------------|---------------|-------------|------------------|-------------------|--------------------------|-------------|
| iShares Russell 2000 Growth ETF | Mutual Fund | United States | 34,037 | 0.21 | -555 | -0.02 | 31-Jan-2015 |
| Guggenheim Investments | Investment Advisor/ Hedge Fund | United States | 2,195 | 0.01 | 0 | 0 | 31-Jan-2015 |
| iShares Russell 3000 ETF | Mutual Fund | United States | 1,267 | 0.01 | 19 | 0.02 | 31-Jan-2015 |
| DB Platinum Advisors | Investment Advisor | Luxembourg | 1,001 | 0.01 | 0 | 0 | 31-Jan-2015 |
| ProFund Advisors LLC | Investment Advisor | United States | 985 | 0.01 | 0 | 0 | 31-Jan-2015 |
| Nuveen Asset Management, LLC | Investment Advisor/ Hedge Fund | United States | 378 | 0 | 0 | 0 | 31-Jan-2015 |
| iShares Russell 3000 Growth ETF | Mutual Fund | United States | 234 | 0 | -80 | -0.25 | 31-Jan-2015 |
| ProShares Hedge Replication ETF | Mutual Fund | United States | 5 | 0 | 0 | 0 | 31-Jan-2015 |

[Return to Table of Contents](#)



| | 2011 | 2012 | 2013 | | |
|--------------------------|---------|---------|---------|--|--|
| Sales (USD M) | 0 | 0 | 1.334 | | |
| Operating Income (USD M) | -12.678 | -19.476 | -16.199 | | |
| Net Income (USD M) | -12.826 | -19.657 | -18.025 | | |

[Return to Table of Contents](#)

Quarterly earnings update

| Period | Sales (USD M) | Operating Income (USD M) | Net Income (USD M) |
|---------|---------------|--------------------------|--------------------|
| 2014 Q3 | 0.539 | -10.602 | -10.674 |
| 2014 Q2 | 0.761 | -8.045 | -8.121 |
| 2014 Q1 | 0.568 | -7.189 | -7.741 |
| 2013 Q4 | 0.51 | -4.12 | -6.208 |
| 2013 Q3 | 0.622 | -3.54 | -4.718 |
| 2013 Q2 | 0.202 | -3.383 | -4.551 |
| 2013 Q1 | 0 | -5.435 | -6.405 |
| 2012 Q4 | 0 | -5.028 | -6.004 |
| 2012 Q3 | 0 | -4.762 | -5.735 |

BALANCE SHEET

Assets (USD M)

| | 2011 | 2012 | 2013 | | |
|-------------------------------------|-------|-------|--------|--|--|
| Cash & Short Term Investments | 0.7 | 8.016 | 7.942 | | |
| Inventories - Total | 0 | 0 | 0 | | |
| Current Assets - Total | 0.989 | 8.271 | 8.03 | | |
| Property, Plant And Equipment - Net | 1.535 | 1.197 | 0.759 | | |
| Other Assets - Total | 0.007 | 0.035 | 2.354 | | |
| Total Assets | 2.665 | 9.503 | 11.237 | | |

Liabilities (USD M)

| | 2011 | 2012 | 2013 | | |
|---|-------|-------|-------|--|--|
| Accounts Payable | 1.057 | 1.107 | 1.746 | | |
| Short Term Debt & Current Portion Of Long Term Debt | 0.61 | 0.236 | 1.642 | | |
| Current Liabilities - Total | 2.218 | 1.825 | 5.353 | | |
| Long Term Debt | 0.419 | 1.769 | 2.876 | | |
| Other Liabilities | 0.175 | 0.17 | 0.307 | | |
| Total Liabilities | 2.812 | 3.764 | 8.891 | | |

[Return to Table of Contents](#)

Stockholders Equity (USD M)

| | 2011 | 2012 | 2013 | | |
|--|--------|--------|--------|--|--|
| Minority Interest | 0 | 0 | 0 | | |
| Preferred Stock | 19.644 | 45.035 | 66.523 | | |
| Common Stock | 0.006 | 0.008 | 0.002 | | |
| Treasury Stock | 0 | 0 | | | |
| Total Liabilities & Shareholders' Equity | 2.665 | 9.503 | 11.237 | | |

FORECASTS

EPS Forecast

| Year ending | Current Forecast | 1 month ago | 3 months ago |
|-------------|------------------|-------------|--------------|
| 31-Dec-2015 | -1.59 | -1.55 | -1.6 |
| 31-Dec-2016 | -1.51 | -1.48 | -1.52 |
| 31-Dec-2017 | -2 | -2.02 | -2 |

Other Forecasts

| Year ending | DPS | CPS | Pretax | Sales |
|-------------|-----|-----|--------|-------|
| 31-Dec-2015 | 0 | | -29.15 | 0.5 |
| 31-Dec-2016 | 0 | | -31.85 | 0 |
| 31-Dec-2017 | | | -40.3 | 43 |

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|-------------------------|--------|----------|-------|
| Inflammatory disease | 1 | 3 | 4 |
| Immune disorder | 1 | 3 | 4 |
| Ocular disease | 3 | 0 | 3 |
| Hematological disease | 0 | 2 | 2 |
| Musculoskeletal disease | 0 | 2 | 2 |
| Genetic disorder | 0 | 1 | 1 |
| Metabolic disorder | 0 | 1 | 1 |
| Dermatological disease | 0 | 1 | 1 |
| Cardiovascular disease | 1 | 0 | 1 |
| Growth disorder | 0 | 1 | 1 |

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 3 Clinical | 1 |
| Discovery | 3 |
| No Development Reported | 5 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--------------------------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Technology - Other Proprietary | 1 | 0 | 0 | 0 | 1 |
| Drug - Funding | 1 | 0 | 0 | 0 | 1 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|----------------------|---------|-----|
| Ocular disease | 1 | 4 |
| Inflammatory disease | 0 | 2 |

[Return to Table of Contents](#)

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 3 | 1 | 1 |
| Phase 2 | 0 | 2 |
| Phase 1 | 0 | 2 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|---------------------------|----------|----------------|-------|
| Cardiovascular disease | 2 | 0 | 2 |
| Endocrine disease | 1 | 1 | 2 |
| Gastrointestinal disease | 3 | 1 | 4 |
| Genitourinary disease | 0 | 1 | 1 |
| Hematological disease | 1 | 0 | 1 |
| Degeneration | 1 | 0 | 1 |
| Immune disorder | 5 | 1 | 6 |
| Musculoskeletal disease | 3 | 0 | 3 |
| Neoplasm | 1 | 2 | 3 |
| Ocular disease | 6 | 0 | 6 |
| Metabolic disorder | 2 | 0 | 2 |
| Neurological disease | 4 | 0 | 4 |
| Respiratory disease | 0 | 1 | 1 |
| Infectious disease | 1 | 1 | 2 |
| Inflammatory disease | 8 | 0 | 8 |
| Gynecology and obstetrics | 0 | 1 | 1 |

[Return to Table of Contents](#)



| | | | |
|------------------------|---|---|---|
| Dermatological disease | 1 | 1 | 2 |
|------------------------|---|---|---|

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

EBI-005

| | |
|-----------------------------|---|
| Drug Name | EBI-005 |
| Key Synonyms | |
| Originator Company | Eleven Biotherapeutics |
| Active Companies | Eleven Biotherapeutics |
| Inactive Companies | |
| Highest Status | Phase 3 Clinical |
| Active Indications | Xerophthalmia, Allergy |
| Target-based Actions | IL-1 antagonist, Type I IL-1 receptor antagonist |
| Other Actions | Ophthalmological agent |
| Technologies | Ophthalmic formulation, Biological therapeutic, Peptide, Protein chimeric |
| Last Change Date | 28-Jan-2015 |

EBI-031

| | |
|-----------------------------|--|
| Drug Name | EBI-031 |
| Key Synonyms | |
| Originator Company | Eleven Biotherapeutics |
| Active Companies | Eleven Biotherapeutics |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Diabetic macular edema |
| Target-based Actions | IL-6 antagonist, Interleukin-6 ligand inhibitor |
| Other Actions | Anti-inflammatory |
| Technologies | Antibody, Injectable formulation, Ophthalmic formulation, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 28-Jan-2015 |

[Return to Table of Contents](#)

EBI-028

| | |
|-----------------------------|---|
| Drug Name | EBI-028 |
| Key Synonyms | |
| Originator Company | Eleven Biotherapeutics |
| Active Companies | Eleven Biotherapeutics |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Inflammatory disease |
| Target-based Actions | IL-17 antagonist |
| Other Actions | Anti-inflammatory, Topical antipsoriatic product |
| Technologies | Injectable formulation, Dermatological formulation, Ophthalmic formulation, Biological therapeutic, Parenteral formulation unspecified, Peptide |
| Last Change Date | 16-May-2014 |

eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics

| | |
|-----------------------------|---|
| Drug Name | eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics |
| Key Synonyms | |
| Originator Company | ThromboGenics NV |
| Active Companies | Eleven Biotherapeutics, ThromboGenics NV |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Diabetic eye disease |
| Target-based Actions | |
| Other Actions | Ophthalmological agent, Unspecified drug target |
| Technologies | Biological therapeutic, Parenteral formulation unspecified, Protein recombinant |
| Last Change Date | 10-Oct-2014 |

[Return to Table of Contents](#)


This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

